Cargando…

Assessment of efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream: an Indian multicentric study on melasma

INTRODUCTION: Melasma is one of the commonly reported pigmentory disorders in the Indian population. Numerous therapeutic modalities are available. However, very few have produced complete satisfactory response. 4-n-Butylresorcinol 0.3% cream has recently been introduced in India as a new hypopigmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Madan Mohan, NT, Gowda, Adarsh, Jaiswal, Ashok Kumar, Sharath Kumar, BC, Shilpashree, P, Gangaboraiah, Bilugumba, Shamanna, Manjula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725640/
https://www.ncbi.nlm.nih.gov/pubmed/26855596
http://dx.doi.org/10.2147/CCID.S89451
_version_ 1782411659003822080
author Madan Mohan, NT
Gowda, Adarsh
Jaiswal, Ashok Kumar
Sharath Kumar, BC
Shilpashree, P
Gangaboraiah, Bilugumba
Shamanna, Manjula
author_facet Madan Mohan, NT
Gowda, Adarsh
Jaiswal, Ashok Kumar
Sharath Kumar, BC
Shilpashree, P
Gangaboraiah, Bilugumba
Shamanna, Manjula
author_sort Madan Mohan, NT
collection PubMed
description INTRODUCTION: Melasma is one of the commonly reported pigmentory disorders in the Indian population. Numerous therapeutic modalities are available. However, very few have produced complete satisfactory response. 4-n-Butylresorcinol 0.3% cream has recently been introduced in India as a new hypopigmenting agent. It is a resorcinol derivative and acts by inhibiting both tyrosinase and tyrosinase-related protein-1. OBJECTIVE: The available published literatures are with 4-n-butylresorcinol 0.1% cream, and there is paucity of clinical studies with 4-n-butylresorcinol 0.3% cream. Furthermore, considering the fact that Indian skin is more prone to irritation with hypopigmenting agents, our study explores the efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream in Indian subjects with melasma. METHODS: Fifty-two subjects with melasma participated in this open-label, single arm, observational study. All the patients were advised twice daily application of 4-n-butylresorcinol 0.3% cream for 8 weeks over the areas of melasma. Assessment parameters included modified Melasma Area Severity Index (mMASI) score. Digital photographs of all the patients at baseline, week 4, and week 8 were taken. During this 8-week study period, all the adverse events were observed and recorded. RESULTS: All the 52 subjects completed the study. Out of 52 subjects, 90.38% were females. The mean age of patients was 38.5±7.8 years. Mean ± standard error of MASI score measurements showed a significant decrease from baseline score of 14.73±0.59 to 11.09±0.53 after week 4 (P<0.001) and 6.48±0.43 at week 8 (P<0.001). The digital photographs of the study subjects taken at week 4 and week 8 also showed decrease in melasma pigmentation compared to baseline photograph and correlated with the changes in the mMASI score. The treatment was well tolerated by all the study subjects. No adverse reactions were reported throughout the study period. CONCLUSION: Our data suggest that the 4-n-butylresorcinol 0.3% cream is safe, effective, and well tolerated in Indian patients with melasma.
format Online
Article
Text
id pubmed-4725640
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-47256402016-02-05 Assessment of efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream: an Indian multicentric study on melasma Madan Mohan, NT Gowda, Adarsh Jaiswal, Ashok Kumar Sharath Kumar, BC Shilpashree, P Gangaboraiah, Bilugumba Shamanna, Manjula Clin Cosmet Investig Dermatol Original Research INTRODUCTION: Melasma is one of the commonly reported pigmentory disorders in the Indian population. Numerous therapeutic modalities are available. However, very few have produced complete satisfactory response. 4-n-Butylresorcinol 0.3% cream has recently been introduced in India as a new hypopigmenting agent. It is a resorcinol derivative and acts by inhibiting both tyrosinase and tyrosinase-related protein-1. OBJECTIVE: The available published literatures are with 4-n-butylresorcinol 0.1% cream, and there is paucity of clinical studies with 4-n-butylresorcinol 0.3% cream. Furthermore, considering the fact that Indian skin is more prone to irritation with hypopigmenting agents, our study explores the efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream in Indian subjects with melasma. METHODS: Fifty-two subjects with melasma participated in this open-label, single arm, observational study. All the patients were advised twice daily application of 4-n-butylresorcinol 0.3% cream for 8 weeks over the areas of melasma. Assessment parameters included modified Melasma Area Severity Index (mMASI) score. Digital photographs of all the patients at baseline, week 4, and week 8 were taken. During this 8-week study period, all the adverse events were observed and recorded. RESULTS: All the 52 subjects completed the study. Out of 52 subjects, 90.38% were females. The mean age of patients was 38.5±7.8 years. Mean ± standard error of MASI score measurements showed a significant decrease from baseline score of 14.73±0.59 to 11.09±0.53 after week 4 (P<0.001) and 6.48±0.43 at week 8 (P<0.001). The digital photographs of the study subjects taken at week 4 and week 8 also showed decrease in melasma pigmentation compared to baseline photograph and correlated with the changes in the mMASI score. The treatment was well tolerated by all the study subjects. No adverse reactions were reported throughout the study period. CONCLUSION: Our data suggest that the 4-n-butylresorcinol 0.3% cream is safe, effective, and well tolerated in Indian patients with melasma. Dove Medical Press 2016-01-21 /pmc/articles/PMC4725640/ /pubmed/26855596 http://dx.doi.org/10.2147/CCID.S89451 Text en © 2016 Madan Mohan et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Madan Mohan, NT
Gowda, Adarsh
Jaiswal, Ashok Kumar
Sharath Kumar, BC
Shilpashree, P
Gangaboraiah, Bilugumba
Shamanna, Manjula
Assessment of efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream: an Indian multicentric study on melasma
title Assessment of efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream: an Indian multicentric study on melasma
title_full Assessment of efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream: an Indian multicentric study on melasma
title_fullStr Assessment of efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream: an Indian multicentric study on melasma
title_full_unstemmed Assessment of efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream: an Indian multicentric study on melasma
title_short Assessment of efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream: an Indian multicentric study on melasma
title_sort assessment of efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream: an indian multicentric study on melasma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725640/
https://www.ncbi.nlm.nih.gov/pubmed/26855596
http://dx.doi.org/10.2147/CCID.S89451
work_keys_str_mv AT madanmohannt assessmentofefficacysafetyandtolerabilityof4nbutylresorcinol03creamanindianmulticentricstudyonmelasma
AT gowdaadarsh assessmentofefficacysafetyandtolerabilityof4nbutylresorcinol03creamanindianmulticentricstudyonmelasma
AT jaiswalashokkumar assessmentofefficacysafetyandtolerabilityof4nbutylresorcinol03creamanindianmulticentricstudyonmelasma
AT sharathkumarbc assessmentofefficacysafetyandtolerabilityof4nbutylresorcinol03creamanindianmulticentricstudyonmelasma
AT shilpashreep assessmentofefficacysafetyandtolerabilityof4nbutylresorcinol03creamanindianmulticentricstudyonmelasma
AT gangaboraiahbilugumba assessmentofefficacysafetyandtolerabilityof4nbutylresorcinol03creamanindianmulticentricstudyonmelasma
AT shamannamanjula assessmentofefficacysafetyandtolerabilityof4nbutylresorcinol03creamanindianmulticentricstudyonmelasma